Mª Luz Amigo Lozano

Hurtado AM, Luengo-Gil G, Chen-Liang TH, Amaral F, Batta K, Palomo L, Lumbreras E, Przychodzen B, Caparros E, Amigo ML, Dıez-Campelo M, Zamora L, Salido Fierrez EJ, Maciejewski JP, Ortuño FJ, Vicente V, Del Canizo M, Sole F, Ferrer-Marin F, Wiseman DH, Jerez A. Transcriptomic rationale for synthetic lethality-targeting ERCC1 and CDKN1A in chronic myelomonocytic leukaemia. Br J Haematol. 2018 Aug;182(3):373-383. doi: 10.1111/bjh.15408. Epub 2018 May 24. PubMed PMID: 29797327.

AÑO: 2018; IF: 8.615

29797327

Chen-Liang TH, Casado-Prieto AM, Campos-Rodríguez V, Hurtado AM, Amigo ML, García-Malo MD, Vicente V, Ortuño FJ, Jerez A. An increased percentage of myeloid CD34+ bone marrow cells stratifies intermediate IPSS-R myelodysplastic syndrome patients into prognostically significant groups. Int J Lab Hematol. 2018 May 18. doi: 10.1111/ijlh.12860. [Epub ahead of print] PubMed PMID: 29774987.

AÑO: 2018; IF: 2.073

29774987

Ribera JM, García O, Moreno MJ, Barba P, García-Cadenas I, Mercadal S, Montesinos P, Barrios M, González-Campos J, Martínez-Carballeira D, Gil C, Ribera J, Vives S, Novo A, Cervera M, Serrano J, Lavilla E, Abella E, Tormo M, Amigo ML, Artola MT, Genescà E, Bravo P, García-Belmonte D, García-Guiñón A, Hernández-Rivas JM, Feliu E; PETHEMA Group of the Spanish Society of Hematology. Incidence and outcome after first molecular versus overt recurrence in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia included in the ALL Ph08 trial from the Spanish PETHEMA Group. Cancer. 2019 Aug 15;125(16):2810-2817. doi: 10.1002/cncr.32156. Epub 2019 Apr 23. PubMed PMID: 31012967.

AÑO: 2019; IF: 5.772

31012967

Bravo-Perez C, Pajares I, Muiña B, Escobar H, Amigo ML, Garcia-Malo MD, Garcia J, Rodriguez-Pinilla SM, Piris MA, Ortuño FJ. Double hit B cell precursor leukemia/lymphoma in a patient with a prior diagnosis of follicular lymphoma: a diagnostic and therapeutic dilemma. Ann Hematol. 2019 Dec;98(12):2837-2839. doi: 10.1007/s00277-019-03829-1. Epub 2019 Nov 11. PubMed PMID: 31712881.

AÑO: 2019; IF: 2.904

31712881

Hurtado López AM, Chen-Liang TH, Zurdo M, Carrillo-Tornel S, Panadero J, Salido EJ, Beltrán V, Muiña B, Amigo M, Navarro-Villamor N, Cifuentes R, Calabria I, Antón AI, Teruel R, Muro M, Vicente V, Jerez A. Cancer testis antigens in myelodysplastic syndromes revisited: a targeted RNA-seq approach. Oncoimmunology. 2020 Oct 1;9(1):1824642. doi: 10.1080/2162402X.2020.1824642. PubMed PMID: 33101773; PubMed Central PMCID: PMC7553508.

AÑO: 2020; IF: 8.11

33101773